Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

Targeting RSPO3 Reduces Stem Cell Function in PTPRK–RSPO3 Colon Tumors

DOI: 10.1158/2159-8290.CD-RW2016-005 Published February 2016
  • Article
  • Figures & Data
  • Info & Metrics
Loading
  • Major finding: Inhibition of RSPO3 induces differentiation of PTPRK–RSPO3 fusion–positive colon tumors.

  • Mechanism: RSPO3 regulates stem cell function in PTPRK–RSPO3 fusion–positive colon tumors.

  • Impact: Properties of the stem cell–like fraction in colorectal cancer may be therapeutically targeted.

Figure1

Molecular characterization of colorectal cancer has shown that the majority exhibit WNT pathway activation, but effective WNT pathway inhibitors acting at the level of or downstream of β-catenin have been difficult to develop. A subset of colorectal cancer tumors with WNT pathway activation was found to harbor a fusion involving protein tyrosine phosphatase, receptor type, K (PTPRK) and R-spondin 3 (RSPO3). R-spondins have previously been shown to amplify WNT signaling, prompting Storm and colleagues to generate function-blocking antibodies against RSPO2 and RSPO3 to treat two colorectal cancer patient–derived xenografts (PDX) harboring the PTPRK–RSPO3 fusion. Treatment with anti-RSPO3 resulted in growth inhibition of both PDXs, which were shown by histopathologic analysis to be differentiated, contain large amounts of mucus, and exhibit reduced proliferation. Consistent with these results, RNA sequencing of treated tumors revealed that two markers of intestinal stem cells, leucine-rich repeat containing G protein–coupled receptor 5 (LGR5) and achaete-scute family BHLH transcription factor 2 (ASCL2), were among the most significantly downregulated genes, while WNT target genes were modestly downregulated, suggesting that RSPO3 amplifies WNT signaling to meet stem-cell requirements. In addition, markers of differentiation were upregulated in treated cells. In normal intestine, the combination of anti-RSPO2 and anti-RSPO3 profoundly reduced regeneration after irradiation whereas single-antibody treatment had minimal effect, indicating that RSPO2 and RSPO3 both regulate normal stem cell function and are functionally redundant. In line with this finding, treatment of mice bearing serially transplanted PDX tumors with anti-RSPO3 resulted in a marked reduction of both tumor engraftment and cells positive for CD133 and CD44, two markers of colorectal cancer–initiating cells. Together, these results suggest that therapeutically targeting RSPO3 promotes differentiation of the stem-cell compartment of RSPO3 fusion–positive tumors, thus reducing WNT pathway activity, and may induce fewer side effects due to the functional redundancy of R-spondins in normal colon.

Storm EE, Durinck S, de Sousa e Melo F, Tremayne J, Kljavin N, Tan C, et al. Targeting PTPRK–RSPO3 colon tumours promotes differentiation and loss of stem-cell function. Nature 2016;529:97–100.

  • ©2016 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 6 (2)
February 2016
Volume 6, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Targeting RSPO3 Reduces Stem Cell Function in PTPRK–RSPO3 Colon Tumors
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Targeting RSPO3 Reduces Stem Cell Function in PTPRK–RSPO3 Colon Tumors
Cancer Discov February 1 2016 (6) (2) OF5; DOI: 10.1158/2159-8290.CD-RW2016-005

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Targeting RSPO3 Reduces Stem Cell Function in PTPRK–RSPO3 Colon Tumors
Cancer Discov February 1 2016 (6) (2) OF5; DOI: 10.1158/2159-8290.CD-RW2016-005
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Figures & Data
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Structures Identify Selpercatinib and Pralsetinib Resistance Mechanisms
  • Cryo-EM Structures Reveal Mechanism of Anticancer MCT1 Inhibitors
  • Computational Tool Characterizes Previously Unidentified Tumor Subtypes
Show more Research Watch

Colorectal Cancer

  • Differentiation of Cancer Stem Cells Halts Protein and rRNA Synthesis
  • The Cytoplasmic Sensor NLRC3 Inhibits mTOR Signaling in Tumors
  • Epithelial Calcineurin Promotes Microbiota-Dependent Colorectal Cancer
Show more Colorectal Cancer
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement